TriangleCobimetinib (NCT04079179)
Cobimetinib trial for Langerhan's Cell Histiocytosis (NCT04079179). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for patients aged six months or older with qualifying Langerhans cell histiocytosis or other histiocytic disorders. Disease and prior-treatment rules vary by age. Children must weigh at least 20 kilograms, and everyone must swallow tablets.
The idea: cobimetinib blocks MEK growth signals. Treatment runs 21 days on, seven days off, for twelve cycles. A BRAF mutation is not required.
This phase 2 study plans 90 patients. Carl Allen at Baylor College of Medicine chairs the study, with ten recruiting US sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.